 | Up a level |
Peyvandi, Flora; Cataland, Spero; Scully, Marie; Coppo, Paul; Knoebl, Paul; Kremer Hovinga, Johanna A.; Metjian, Ara; de la Rubia, Javier; Pavenski, Katerina; Minkue Mi Edou, Jessica; De Winter, Hilde; Callewaert, Filip (2021). Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood advances, 5(8), pp. 2137-2141. American Society of Hematology 10.1182/bloodadvances.2020001834
Knoebl, Paul; Cataland, Spero; Peyvandi, Flora; Coppo, Paul; Scully, Marie; Kremer Hovinga, Johanna A.; Metjian, Ara; de la Rubia, Javier; Pavenski, Katerina; Minkue Mi Edou, Jessica; De Winter, Hilde; Callewaert, Filip (2020). Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. Journal of thrombosis and haemostasis, 18(2), pp. 479-484. Wiley-Blackwell 10.1111/jth.14679
Cataland, Spero R; Peyvandi, Flora; Mannucci, Pier M; Lämmle, Bernhard; Kremer Hovinga, Johanna A; Machin, Samuel J; Scully, Marie; Rock, Gail; Gilbert, James C; Yang, Shangbin; Wu, Haifeng; Jilma, Bernd; Knoebl, Paul (2011). Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. American journal of hematology, 87(4), pp. 430-2. New York, N.Y.: Wiley-Liss 10.1002/ajh.23106
